

What's New for the 2009 Physician Quality Reporting Initiative (PQRI)

http://www.cms.hhs.gov/PQRI

This fact sheet includes important information about the 2009 PQRI. Similar to the 2008 PQRI, eligible professionals can choose whether to report quality measures data through claims submission or through a qualified PQRI registry. In addition, eligible professionals can choose to report on individual guality measures or on measures groups

Registry Reporting

CMS will conduct another self-nomination process for registries so additional registries can potentially be approved for submitting quality measures data for the 2009 PQRI. Registries qualified to submit data on behalf of their eligible professionals in 2008 are not required to self-nominate again for 2009 unless they are unsuccessful at submitting 2008 data by March 31, 2009. The list of gualified registries for the 2009 PQRI will be available at http://www.cms.hhs.gov/PQRI on the CMS website.

Important Changes for the 2009 PQRI

The definition of "eligible professional" has been expanded to include qualified audiologists.

Eligible professionals who satisfactorily report at least three applicable guality measures shall be paid an incentive of 2.0% of estimated allowable charges submitted not later than 2 months after the end of the reporting period for 2009 PQRI quality measures. This is an increase of 0.5% from the incentive amount authorized for the 2008 PQRI.

If fewer than three PQRI quality measures apply to an eligible professional, he or she may still qualify for the 2.0% PQRI incentive payment by satisfactorily submitting quality-data codes for all applicable measures through claims submission. However, eligible professionals who satisfactorily submit quality-data codes for fewer than three PQRI measures will be subject to a measure-applicability validation (MAV) process to determine whether they should have submitted quality-data codes for additional measures.

The MAV process will be applied to determine whether quality-data codes for additional measures should have been submitted when eligible professionals satisfactorily submit quality-data codes for fewer than three PQRI measures. MAV consists of a two-step process: (1) a "clinical relation" test, and (2) a "minimum threshold" test. Those who fail the validation process will not earn the PQRI incentive payment for 2009. A detailed document describing how MAV will be applied for the 2009 PQRI will be available as a downloadable document in the Analysis/Payment section at http://www.cms.hhs.gov/PQRI on the CMS website.

2009 PQRI Individual Quality Measures

The final number of 2009 PQRI quality measures is 153. This total includes 52 new measures. Whereas all 2008 PQRI quality measures were reportable through claims submission or through a qualified PQRI registry, a subset of the 2009 PQRI quality measures is reportable only through registries.

Appendix 1 lists 18 measures removed from the 2008 PQRI measures for 2009, Appendix 2 identifies the new measures, and Appendix 3 identifies 18 measures reportable only through registries in 2009.

Important Note: The detailed measure specifications for the 2008 PQRI guality measures selected for the 2009 PQRI may have been updated or modified during the National Quality Forum (NQF) endorsement process or for other reasons prior to 2009. The 2009 PQRI quality measure specifications for any given quality measure may, therefore, be different from specifications for the same quality measure used for 2008. Specifications for all 2009 PQRI quality measures, whether or not included in the 2008 PQRI program, must be obtained from the 2009 PQRI Quality Measures Specifications Manual for 2009 PQRI quality measures, which is available as a downloadable document in the Measures/ Codes section at http://www.cms.hhs.gov/PQRI on the CMS website.

ICN: 901503

This fact sheet was prepared as a service to the public and is not intended to grant rights or impose obligations. This fact sheet may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.

2009 PQRI Measures Groups

For 2009 there are 7 measures groups.

Appendix 4 includes measures numbers, titles, and sources for each measures group: 1) Diabetes Mellitus,
2) Chronic Kidney Disease, 3) Preventive Care, 4) Rheumatoid Arthritis,
5) Coronary Artery Bypass Graft (CABG) Surgery, 6) Perioperative Care, and 7) Back Pain.

The first three measures groups were retained from last year; however, except for the Preventive Care measures group, the measures selected for inclusion in these measures groups are different from the measures that were included in the 2008 measures groups. Please note that the ESRD measures group is removed from the PQRI for 2009.

In addition, measures groups specifications are different from those specifications for individually reported measures that form the group. Therefore, the specifications and reporting instructions for the 2009 PQRI measures groups are provided separately in the 2009 PQRI Measures Groups Specifications Manual available as a downloadable document in the Measures/Codes section at http://www.cms.hhs.gov/PQRI on the CMS website. Please note that new for 2009, if **all** quality actions for the applicable measures in a measures group have been performed for the patient, **one G-code** may be reported in lieu of the individual quality-data codes for each of the measures within the group.

Important Note: The measures in the Back Pain measures group are reportable solely as a measures group and not as individual quality measures. In addition, some of the measures in the CABG Surgery measures group are reportable only through a qualified PQRI registry. Therefore, the CABG Surgery measures group is reportable only through a qualified PQRI registry and is not reportable through claims submission.

2009 PQRI Reporting Options & Criteria for Satisfactory Reporting

In total, there are 9 reporting options or ways in which an eligible professional can satisfactorily report for the 2009 PQRI. Although there are multiple reporting options for satisfactory reporting, an eligible professional only needs to satisfactorily report under one option to qualify for the 2.0% PQRI incentive payment for the applicable reporting period.

Important Note: Although the number of reporting options remains the same as in the 2008 PQRI, there are some differences between the 2008 PQRI reporting criteria and the 2009 reporting criteria. The criteria that will be used to determine whether an eligible professional satisfactorily reports for the 2009 PQRI are summarized in Tables 1 through 4 below.

Table 1: Criteria for Claims-based Reporting of Individual Measures

Reporting Criteria	Reporting Period
At least 3 PQRI measures, or 1-2 measures if less than	January 1, 2009 –
3 apply to the eligible professional, for 80% of applicable	December 31, 2009
Medicare Part B FFS patients of each eligible professional.	

Table 2: Criteria for Claims-based Reporting of Measures Groups

Reporting Criteria	Reporting Period
One measures group for 30 consecutive Medicare Part B FFS patients of each eligible professional.	January 1, 2009 – December 31, 2009
One measures group for 80% of applicable Medicare Part B FFS patients of each eligible professional (with a minimum of 30 patients during the reporting period).	January 1, 2009 – December 31, 2009
One measures group for 80% of applicable Medicare Part B FFS patients of each eligible professional (with a minimum of 15 patients during the reporting period).	July 1, 2009 – December 31, 2009

Table 3: Criteria for Registry-based Reporting of Individual Measures

Reporting Criteria	Reporting Period
At least 3 PQRI measures for 80% of applicable Medicare	January 1, 2009 –
Part B FFS patients of each eligible professional.	December 31, 2009
At least 3 PQRI measures for 80% of applicable Medicare	July 1, 2009 –
Part B FFS patients of each eligible professional.	December 31, 2009

Table 4: Criteria for Registry-based Reporting of Measures Groups

Reporting Criteria	Reporting Period
One measures group for 30 consecutive patients of each eligible professional. Patients may include, but may not be exclusively, non-Medicare Part B FFS patients.	January 1, 2009 – December 31, 2009
One measures group for 80% of applicable Medicare Part B FFS patients of each eligible professional (with a minimum of 30 patients during the reporting period).	January 1, 2009 – December 31, 2009
One measures group for 80% of applicable Medicare Part B FFS patients of each eligible professional (with a minimum of 15 patients during the reporting period).	July 1, 2009 – December 31, 2009

Public Reporting of 2009 PQRI Data

For 2009 PQRI submitted data, CMS plans to post the names of individual eligible professionals who satisfactorily report quality measures for the 2009 PQRI following completion of 2009 incentive payments.

Appendix 1: 2008 PQRI Measures Removed for 2009

Measure Number	Measure Title	
	Measure Title	
4	Screening for Future Fall Risk	
73	Plan for Chemotherapy Documented Before Chemotherapy Administered	
74	Radiation Therapy Recommended for Invasive Breast Cancer Patients who have Undergone Breast Conserving Surgery	
75	Prevention of Ventilator-Associated Pneumonia – Head Elevation	
77	Assessment of GERD Symptoms in Patients Receiving Chronic Medication for GERD	
78	Vascular Access for Patients Undergoing Hemodialysis	
80	Plan of Care for ESRD Patients with Anemia	
88	Hepatitis A and B Vaccination in Patients with HCV	
96	Otitis Media with Effusion (OME): Antihistamines or Decongestants – Avoidance of Inappropriate Use	
97 Otitis Media with Effusion (OME): Systemic Antimicrobials – Avoidance of Inapp		
98	Otitis Media with Effusion (OME): Systemic Corticosteroids – Avoidance of Inappropriate Use	
101	Appropriate Initial Evaluation of Patients with Prostate Cancer	
103	Review of Treatment Options in Patients with Clinically Localized Prostate Cancer	
120	ACE Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy in Patients with CKD	
125	HIT – Adoption/Use of e-Prescribing	
129	Universal Influenza Vaccine Screening and Counseling	
132	Patient Co-Development of Treatment Plan/Plan of Care	
133	Screening for Cognitive Impairment	

Measure Number	Measure Title	Measure Source
135	Chronic Kidney Disease (CKD): Influenza Immunization	American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI)
136	Melanoma: Follow-Up Aspects of Care	AMA-PCPI/ National Committee for Quality Assurance (NCQA)
137	Melanoma: Continuity of Care – Recall System	AMA-PCPI/NCQA
138	Melanoma: Coordination of Care	AMA-PCPI/NCQA
139	Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement	AMA-PCPI/NCQA
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	AMA-PCPI/NCQA
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	AMA-PCPI/NCQA
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	AMA-PCPI
143	Oncology: Medical and Radiation – Pain Intensity Quantified	AMA-PCPI
144	Oncology: Medical and Radiation – Plan of Care for Pain	AMA-PCPI
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	AMA-PCPI/NCQA
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	AMA-PCPI
147	Nuclear Medicine: Correlation with Existing Imaging Studies for all Patients Undergoing Bone Scintigraphy	AMA-PCPI
148*	Back Pain: Initial Visit	NCQA
149*	Back Pain: Physical Exam	NCQA
150*	Back Pain: Advice for Normal Activities	NCQA
151*	Back Pain: Advice Against Bed Rest	NCQA
152	Coronary Artery Disease (CAD): Lipid Profile in Patients with CAD	AMA-PCPI
153	Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	AMA-PCPI
154	Falls: Risk Assessment	AMA-PCPI
155	Falls: Plan of Care	AMA-PCPI
156	Oncology: Radiation Dose Limits to Normal Tissues	AMA-PCPI
157	Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	Society of Thoracic Surgeons (STS)
158	Endarterectomy: Use of Patch During Conventional Endarterectomy	STS
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	AMA-PCPI/NCQA
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	AMA-PCPI/NCQA

*These measures are reportable solely as part of the Back Pain measures group and not as individual quality measures.

(Continued on next page)

Appendix 2: New PQRI Measures in 2009 and Their Source (continued)

Measure Number	Measure Title	Measure Source
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	AMA-PCPI/NCQA
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	AMA-PCPI/NCQA
163	Diabetes Mellitus: Foot Exam	NCQA
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation)	STS
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	STS
166	Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA)	STS
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Insufficiency	STS
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	STS
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	STS
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	STS
171	Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling	STS
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	SVS
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	AMA-PCPI
174	Pediatric End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis	AMA-PCPI
175	Pediatric End Stage Renal Disease (ESRD): Influenza Immunization	AMA-PCPI
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	AMA-PCPI/NCQA
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	AMA-PCPI/NCQA
178	Rheumatoid Arthritis (RA): Functional Status Assessment	AMA-PCPI/NCQA
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	AMA-PCPI/NCQA
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	AMA-PCPI/NCQA
181	Elder Maltreatment Screen and Follow-Up Plan	Quality Insights of Pennsylvania (QIP)/CMS
182	Functional Outcome Assessment in Chiropractic Care	QIP/CMS
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	AMA-PCPI
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	AMA-PCPI
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	AMA-PCPI/NCQA
186	Wound Care: Use of Compression System in Patients with Venous Ulcers	AMA-PCPI/NCQA

Appendix 3: 2009 Registry-only PQRI Measures and Their Source

Measure Number	Measure Title	Measure Source
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)	AMA-PCPI
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge	AMA-PCPI/NCQA
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	AMA-PCPI/NCQA
81	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients	AMA-PCPI
82	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis	AMA-PCPI
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	AMA-PCPI/NCQA
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	AMA-PCPI/NCQA
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	AMA-PCPI/NCQA
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	AMA-PCPI/NCQA
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation)	STS
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	STS
166	Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA)	STS
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Insufficiency	STS
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	STS
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	STS
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	STS
171	Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling	STS
174	Pediatric End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis	AMA-PCPI

Appendix 4: Measures Groups

2009 Diabetes Mellitus Measures Group

Measure Number	Measure Title	Measure Source
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	NCQA
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	NCQA
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	NCQA
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	NCQA
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	NCQA
163*	Diabetes Mellitus: Foot Exam	NCQA

*New measures added to this measures group for 2009 are denoted with an asterisk.

2009 Chronic Kidney Disease (CKD) Measures Group

Measure Number	Measure Title	Measure Source
121	Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)	AMA-PCPI
122	Chronic Kidney Disease (CKD): Blood Pressure Management	AMA-PCPI
123	Chronic Kidney Disease (CKD): Plan of Care - Elevated Hemoglobin for Patients Receiving Erythropoiesis - Stimulating Agents (ESA)	AMA-PCPI
135*	Chronic Kidney Disease (CKD): Influenza Immunization	AMA-PCPI
153*	Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	AMA-PCPI

*New measures added to this measures group for 2009 are denoted with an asterisk.

Measure # 120 ACE Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy in Patients with Chronic Kidney Disease (CKD) has been removed from the CKD measures group for 2009.

2009 Preventive Care Measures Group

Measure Number	Measure Title	Measure Source
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	AMA-PCPI/NCQA
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	AMA-PCPI/NCQA
110	Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	AMA-PCPI
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	NCQA
112	Preventive Care and Screening: Screening Mammography	NCQA
113	Preventive Care and Screening: Colorectal Cancer Screening	NCQA
114	Preventive Care and Screening: Inquiry Regarding Tobacco Use	AMA-PCPI
115	Preventive Care and Screening: Advising Smokers to Quit	NCQA
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	QIP/CMS

2009 Rheumatoid Arthritis Measures Group

Measure Number	Measure Title	Measure Source
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	NCQA
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	AMA-PCPI/NCQA
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	AMA-PCPI/NCQA
178	Rheumatoid Arthritis (RA): Functional Status Assess	AMA-PCPI/NCQA
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	AMA-PCPI/NCQA
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	AMA-PCPI/NCQA

2009 CABG Measures Group (reportable only through a qualified PQRI registry)

Measure Number	Measure Title	Measure Source
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	STS
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	STS
164*	Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation)	STS
165*	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	STS
166*	Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA)	STS
167*	Coronary Artery Bypass Graft (CABG): Postoperative Renal Insufficiency	STS
168*	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	STS
169*	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	STS
170*	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	STS
171*	Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling	STS

*This measure is reportable only via registry-based reporting and is not reportable via claims-based reporting.

2009 Perioperative Care Measures Group

Measure Number	Measure Title	Measure Source
20	Perioperative Care: Timing of Antibiotic Prophylaxis - Ordering Physician	AMA-PCPI/NCQA
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	AMA-PCPI/NCQA
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	AMA-PCPI/NCQA
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	AMA-PCPI/NCQA

2009 Back Pain Measures Group

Measure Number	Measure Title	Measure Source
148	Back Pain: Initial Visit	NCQA
149	Back Pain: Physical Exam	NCQA
150	Back Pain: Advice for Normal Activities	NCQA
151	Back Pain: Advice Against Bed Rest	NCQA

The measures in the Back Pain measures group are reportable only as a measures group and not as individual measures.





